We also demonstrated that simultaneous targeting of FGFR1 and GLI1 using GANT61 and AZD4547 inhibitors significantly decreases breast cancer invasion and metastasis, suggesting new approaches for clinical studies. This evidence concerns the gene FGFR1 and breast cancer.